It is important to remember that every drug available in pharmacies has been evaluated in clinical trials.
Clinical trials source: clinicaltrials.gov |
---|
Study 1 |
Bipolar disorder
more information soon.
Check what tests we are currently conducting in our facility.
if you are interested participation in a clinical trial - submit your form to recruiting department
Centrum Badań Klinicznych PI-House sp. z o. o.
NIP: 9571059089 | EU VAT ID: PL9571059089
REGON: 221506777 | KRS: 0000394618
Share capital: PLN 60,000
Entry number in the Register of
Health Care Providers: 000000154510
We have a personal data protection policy in accordance with the GDPR. This site uses cookies to provide services at the highest level. By continuing to use the site, you agree to their use.
Personal Data Administrator is Centrum Badań Klinicznych PI-House Sp. z o. o with its registered office in Gdańsk (80-546), ul. Na Zaspa 3, registered in the Gdańsk-Północ District Court in Gdańsk, VII Commercial Department of the National Court Register under the number KRS: 0000394618, NIP: 9571059089.
Please be advised that the Data Administrator has appointed a Personal Data Protection Inspector. You have the right to contact the Data Protection Officer directly using the email address: iod@pihouse.pl.
Learn more by clicking this link
We run a policy of personal data protection according to ROPE.
Our website uses cookies to improve your experience. By continuing to browse our website, you are agreeing to our use of cookies.
The administrator of Personal Data is the Centrum Badań Klinicznych PI-House Sp. z o. o. with headquarters in Gdańsk (80-546), ul. Na Zaspa 3, registered at the District Court Gdańsk - Północ in Gdańsk, VII Commercial Division of the National Court Register under KRS number: 0000394618, Taxpayer identification number: 9571059089.
Please be advised that the Data Administrator has appointed the Data Protection Inspector. You have the right to contact the Data Protection Supervisor using the e-mail address: iod@pihouse.pl.
Learn more by clicking this link
Study title: Randomized, double-blind, multicentre clinical trial evaluating the efficacy, safety and tolerability of cariprazine in the prevention of recurrence in bipolar I disorder. Patients with current manic or depressive episode, without mixed functions
Therapeutic area: Type I bipolar disorder
Phase: III
Start Date: June 15, 2018
End date: July 17, 2021
Status: Recruiting
Sponsor Name: Allergan
Study title: Open-label long-term safety study of esketamine nasal spray dose extension in treatment-resistant depression
Therapeutic area: Treatment-resistant depressive disorder
Phase: III
Start Date: June 9, 2016
End date: December 31, 2022
Status: Not recruiting
Sponsor Name: Janssen Research & Development, LLC
Study title: Long-term, multicentre, randomized, double-blind, controlled, parallel group study of the safety and efficacy of Lemborekxant in people with insomnia disorders
Therapeutic area: Disorder of insomnia
Phase: III
Start Date: November 15, 2016
End date: January 8, 2019
Status: Not recruiting
Sponsor Name: Eisai Inc.
Study title: Adaptive, multicentre, prospective, randomized, double-blind, placebo-controlled phase IIb / III study of the safety and efficacy of NaBen® (DAAO inhibitor) as an additional treatment for schizophrenia in adults
Therapeutic area: schizophrenia
Phase: IIb / III
Start Date: March 29, 2017
End date: December 31, 2021
Status: Recruiting
Sponsor Name: SyneuRx
Study title: Adaptive Phase II / III study, two-part, double-blind, randomized, placebo-controlled, dose-titled multicenter study of the safety and efficacy of NaBen® as add-on therapy with clozapine for the treatment of symptoms of refractory schizophrenia in adults
Therapeutic area: schizophrenia
Phase: II / III
Start Date: March 29, 2017
End date: December 31, 2021
Status: Recruiting
Sponsor Name: SyneuRx
We have a personal data protection policy in accordance with the GDPR. This site uses cookies to provide services at the highest level. By continuing to use the site, you agree to their use.
Personal Data Administrator is Centrum Badań Klinicznych PI-House Sp. z o. o with its registered office in Gdańsk (80-546), ul. Na Zaspa 3, registered in the Gdańsk-Północ District Court in Gdańsk, VII Commercial Department of the National Court Register under the number KRS: 0000394618, NIP: 9571059089.
Please be advised that the Data Administrator has appointed a Personal Data Protection Inspector. You have the right to contact the Data Protection Officer directly using the email address: iod@pihouse.pl.
Learn more by clicking this link
We run a policy of personal data protection according to ROPE.
Our website uses cookies to improve your experience. By continuing to browse our website, you are agreeing to our use of cookies.
The administrator of Personal Data is the Centrum Badań Klinicznych PI-House Sp. z o. o. with headquarters in Gdańsk (80-546), ul. Na Zaspa 3, registered at the District Court Gdańsk - Północ in Gdańsk, VII Commercial Division of the National Court Register under KRS number: 0000394618, Taxpayer identification number: 9571059089.
Please be advised that the Data Administrator has appointed the Data Protection Inspector. You have the right to contact the Data Protection Supervisor using the e-mail address: iod@pihouse.pl.
Learn more by clicking this link